Cray to Install China's First Cray XC30 Supercomputer at Hong Kong Sanatorium and Hospital

Cray to Install China's First Cray XC30 Supercomputer at Hong Kong Sanatorium and Hospital

SEATTLE, WA -- (Marketwired) -- 03/19/14 -- Global supercomputer leader Cray Inc. (NASDAQ: CRAY) today announced the Company has been awarded a contract to provide the Hong Kong Sanatorium & Hospital (HKSH) with a Cray® XC30™ supercomputer -- the first XC30 system in China. One of the largest private hospitals in Hong Kong, HKSH will use its Cray XC30 system to further medical research in the areas of bioinformatics and next generation sequencing (NGS).

"The Cray supercomputer will advance our mission to provide the best care for our patients and improved outcomes for people worldwide," said Mr. Wyman Li, Manager (Administration) of HKSH. "The XC30 supercomputer will greatly increase our gene sequencing capabilities, enabling us to deliver healthcare innovations even faster."

The Hong Kong Sanatorium & Hospital has a long tradition of using cutting edge medical science and innovative technologies to provide quality medical care for its patients, and HKSH chose Cray for its leadership position in life sciences and supercomputing. The Cray life sciences and performance teams worked closely with the high performance computing (HPC) team at HKSH to understand the unique application requirements and help optimize codes to achieve aggressive performance metrics.

"Recent progress in DNA sequencing technology has yielded a new class of devices that allow for the analysis of genetic material with unprecedented speed and efficiency, and this next-generation technology combined with the state-of-the-art supercomputing capabilities of the Cray XC30 system will be a powerful resource for HKSH," said Mr. Andrew Wyatt Cray vice president, APMEA. "HKSH is one of the most prestigious and internationally accredited private hospitals in China, and we are honored that the country's first Cray XC30 supercomputer will power the innovative life sciences research being pioneered by the researchers at HKSH."

Previously code-named "Cascade," the Cray XC30 supercomputers are Cray's most advanced HPC systems and engineered to meet the performance challenges of today's HPC users. Special features of the Cray XC30 and Cray XC30-AC™ supercomputers include: the Aries system interconnect; a Dragonfly network topology that frees applications from locality constraints; innovative cooling systems to lower customers' total cost of ownership; the next-generation of the scalable, high performance Cray Linux Environment supporting a wide range of applications; Cray's HPC optimized programming environment, and the ability to handle a wide variety of processor types.

The Cray XC30 system is expected to be delivered and installed at HKSH in 2014. Additional information on the Cray XC30 supercomputers can be found on the Cray website at

About Hong Kong Sanatorium & Hospital
Hong Kong Sanatorium & Hospital is one of the leading private hospitals in Hong Kong. With the motto "Quality in Service, Excellence in Care," the Hospital is committed to service the public as well as promoting medical education and research.

About Cray Inc.
Global supercomputing leader Cray Inc. (NASDAQ: CRAY) provides innovative systems and solutions enabling scientists and engineers in industry, academia and government to meet existing and future simulation and analytics challenges. Leveraging 40 years of experience in developing and servicing the world's most advanced supercomputers, Cray offers a comprehensive portfolio of supercomputers and Big Data storage and analytics solutions delivering unrivaled performance, efficiency and scalability. Cray's Adaptive Supercomputing vision is focused on delivering innovative next-generation products that integrate diverse processing technologies into a unified architecture, allowing customers to meet the market's continued demand for realized performance. Go to for more information.

Safe Harbor Statement
This press release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934 and Section 27A of the Securities Act of 1933, including, but not limited to, statements related to Cray's ability to deliver the system required by HKSH when required and that meets HKSH's needs. These statements involve current expectations, forecasts of future events and other statements that are not historical facts. Inaccurate assumptions and known and unknown risks and uncertainties can affect the accuracy of forward-looking statements and cause actual results to differ materially from those anticipated by these forward-looking statements. Factors that could affect actual future events or results include, but are not limited to, the risk that the system required by HKSH is not delivered in a timely fashion or does not perform as expected and such other risks as identified in the Company's annual report on Form 10-K for the year ended December 31, 2013, and from time to time in other reports filed by Cray with the U.S. Securities and Exchange Commission. You should not rely unduly on these forward-looking statements, which apply only as of the date of this release. Cray undertakes no duty to publicly announce or report revisions to these statements as new information becomes available that may change the Company's expectations.

Cray is a registered trademark of Cray Inc. in the United States and other countries, and XC30 and XC30-AC are trademarks of Cray Inc. Other product and service names mentioned herein are the trademarks of their respective owners.

Cray Media:
Nick Davis
[email protected]

Cray Investors:
Paul Hiemstra
[email protected]

Source: Cray Inc.

Sponsored By Metabolon

Five Translational Insights Key to a Successful First-in-Human (FIH) Study – Metabolite-Based Biomarker Discovery and Validation

Translational success rates from pre-clinical animal studies to human clinical trials remain frustratingly low. Learn how metabolomics helps you bridge between the theoretical & practical, between the function & actual activity of your drug molecule to get you closer to the phenotype, sooner.